Financings in Brief: Urohealth Systems:
This article was originally published in The Gray Sheet
Executive Summary
Urohealth Systems: Firm's public offering of 2.5 mil. shares is priced at $8 per share. Urohealth filed a registration statement for the offering in October ("The Gray Sheet" Oct. 7, p. 18). Underwriters led by Bear Stearns, Piper Jaffray and Needham & Company hold an over-allotment option to buy 375,000 additional shares. Separately, Urohealth annouces Nov. 22 that its shares will commerce trading on the NASDAQ market on Nov. 26. Urohealth stock previously traded on the American Stock Exchange...
You may also be interested in...
Purespring Therapeutics: Pioneering Gene Therapy For Kidney Disorders
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.
Sandoz Pioneers Posaconazole And Silodosin In Canada
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
Amarin Pulls Insurer Into Hikma/Vascepa Induced Infringement Suit
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: